Ubs Asset Management Americas Inc Aclaris Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$6.56 - $10.95 $167,837 - $280,155	25,585 Added 29.07%	113,601 $778,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $18,772 - $24,064	1,310 Added 1.51%	88,016 $1.39 Million
Q3 2022 Nov 14, 2022	BUY	$13.07 - $18.22 $5,737 - $7,998	439 Added 0.51%	86,706 $1.36 Million
Q2 2022 Aug 12, 2022	BUY	$10.16 - $17.08 $375,117 - $630,610	36,921 Added 74.82%	86,267 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $158,037 - $238,151	12,880 Added 35.32%	49,346 $717,000
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $69,388 - $97,496	5,186 Added 16.58%	36,466 $656,000
Q2 2021 Aug 16, 2021	BUY	$17.08 - $29.6 $534,262 - $925,888	31,280 New	31,280 $549,000
Q2 2019 Aug 15, 2019	SELL	$2.13 - $7.06 $24,213 - $80,258	-11,368 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$5.63 - $7.84 $64,001 - $89,125	11,368 New	11,368 $0
Q1 2018 May 14, 2018	SELL	$17.08 - $25.64 $163,421 - $245,323	-9,568 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$21.47 - $27.8 $4.81 Million - $6.23 Million	-224,028 Reduced 95.9%	9,568 $0
Q3 2017 Nov 13, 2017	BUY	$23.02 - $28.8 $5.38 Million - $6.73 Million	233,596	233,596 $0

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $253M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.